Introduction The focus of the present paper is to understand why the pharmaceutical companies Eli Lilly and Pfizer failed in the introduction of what was supposed to be priced premium innovative products like the 100% pure synthetic insulin “Humulin” or the inhalable insulin “Exubera” and make the correspondent recommendations for the future develop of the firms. [...]
As we saw in the Eli Lilly case, the company tried to sell products like the synthetic insulin Humulin, where really there was no market that has willing to pay premium prices, no pain found, and as Adams (2002) tells us, first we have to validate the market and ask what product customers want. In this [...]
The company DoCoMo built their strategy for its “i-mode” service around some competitive advantages related with the exclusiveness and restricted access of their for-subscribers content. One main difference form other mobile carriers was that this content was provided by third party partners. Another brilliant decision was to use young people as initial target customers, because [...]
In the year 1995 Eli Lilly and Company (ELC) was enjoying a great success with their results, being by far the largest pharmaceutical firm for diabetes disease in the US, having near the 80 percent of the insulin market. Ron Chance, a Lilly research, said that “We can´t get any better than Humulin. And we can´t [...]